52nd week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150366827 | COMPOSITIONS AND METHODS FOR MIXING AND APPLYING MIXED OXIDANT COMPOSITIONS FOR DAIRY ANIMAL TREATMENT - A method for mixing dairy animal teat dip from water and additives. The method includes a mixing manifold into which the water and additives are fed and mixed in a controlled manner. Mixed teat dip is automatically quality tested and monitored to provide data for controlling quantities of water and additives being fed to the manifold. | 2015-12-24 |
20150366828 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR CANCERS - Compositions and methods that are useful for treating a subject suffering from one or more cancers are provided herein. Such compositions and methods can contain an effective amount of magnesium threonate to be used to support or improve the mental state of a subject. The composition and methods comprising magnesium threonate can also be used to support a cancer treatment. | 2015-12-24 |
20150366829 | DELIVERY OF IBUPROFEN AND OTHER COMPOUNDS - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 2015-12-24 |
20150366830 | TREATMENT OF PAIN WITH TOPICAL DICLOFENAC - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users. | 2015-12-24 |
20150366831 | THROMBORESISTANT/BACTERICIDAL S-NITROSO-N-ACETYLPENICILLAMINE (SNAP)-DOPED NITRIC OXIDE RELEASE POLYMERS WITH ENHANCED STABILITY - A polymeric film includes a polymer matrix having at least one of a discrete RSNO adduct or a polymeric RSNO adduct associated therewith, by: covalent attachment to the polymer matrix; dispersion within the polymer matrix; or both, with the at least one of the discrete RSNO adduct or the polymeric RSNO adduct capable of releasing nitric oxide (NO). The polymer matrix is a polyurethane polymer matrix, a silicone rubber polymer matrix, or a copolymer matrix of polyurethane and silicone rubber. The polymeric film is to exhibit stability under dry conditions at 37° C. and prolonged and controllable NO release rates, when exposed to moisture or light capable of photolyzing an RSNO bond, for a predetermined amount of time from the at least one of the discrete RSNO adduct or the polymeric RSNO adduct. | 2015-12-24 |
20150366832 | CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY - A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer. | 2015-12-24 |
20150366833 | Gel Compositions - Substantially anhydrous topical gel compositions comprising ingenol-3-angelate as a suspension in non-aqueous carriers. | 2015-12-24 |
20150366834 | Opsin-Binding Ligands, Compositions and Methods of Use - Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed. | 2015-12-24 |
20150366835 | Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin - A gene expression signature identifies stage II colon cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin. | 2015-12-24 |
20150366836 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING COLORECTAL CANCER - The present invention is related to a method and pharmaceutical composition for treating colorectal cancer. The pharmaceutical composition comprises an effective amount of 16-hydroxy-cleroda-3,13-dine-15,16-olide as active ingredient, and a pharmaceutically acceptable carrier. The present method and pharmaceutical composition provides good efficacy in treating colorectal cancer. The present invention also establishes an animal model, which provides a better drug screening platform for the research. | 2015-12-24 |
20150366837 | SELAMECTIN FOR TREATMENT OF SEA LICE INFESTATIONS - The invention describes a method for treating a parasitic infection or infestation, particularly sea lice, in a fish by administering an effective amount of selamectin. | 2015-12-24 |
20150366838 | METHOD FOR TREATING CANCER WITH A COMBINATION OF QUERCETIN AND A CHEMOTHERAPY AGENT - A method for treating cancer with a combination of a chemotherapy agent and a composition that includes quercetin. The composition can also include one or more of vitamin B3, vitamin C, and folic acid. | 2015-12-24 |
20150366839 | Schisantherin A for the treatment of neurodegenerative diseases - This invention is directed to the use of Schisantherin A or Schizandrin C in treating and/preventing neurodegenerative diseases. | 2015-12-24 |
20150366840 | SALVINORIN COMPOSITIONS AND USES THEREOF - The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin compositions to treat diseases and disorders associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation. For example, salvinorin compositions may be administered to subjects with cardiac arrest, subarachnoid hemorrhage, stroke, cerebral vascular spasm, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment. | 2015-12-24 |
20150366841 | Pd-Ib for Treating Inflammation - The present invention provides a compound, namely (+)-3′-Angeloyloxy-4′-keto-3′, 4′-dihydroseselin (Pd-Ib) derived from | 2015-12-24 |
20150366842 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS - The invention relates to (among other things) oligomer-containing pyrrolidine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 2015-12-24 |
20150366843 | Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy - The present invention concerns the use of methods for evaluating β-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a β-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a β-blocker. Accordingly, methods of treatment are also described. | 2015-12-24 |
20150366844 | COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA - A composition for the treatment of cancerous cells. The composition including a combination of at least one tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor. This combinatorial approach involves direct inhibition of the thioredoxin molecule (and not the enzyme of Trx reductase). | 2015-12-24 |
20150366845 | PHARMACEUTICAL COMPOSITION FOR DISEASES CAUSED BY PATHOGENIC MICROORGANISMS SUCH AS ASPERGILLUS - An object is to provide means for precisely treating pneumonia caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for pneumonia, comprising a compound represented by the following general formula (1) as an active ingredient: (In the formula, R represents a halogen atom or a hydrogen atom, and X represents a halogen atom.) | 2015-12-24 |
20150366846 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS - Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy. | 2015-12-24 |
20150366847 | COMBINATION OF GERANYLGERANYLACETONE AND IBUDILAST AND METHODS OF USING SAME - The present invention relates generally to methods for treating progressive neurodegenerative diseases, including their progressive forms. In particular, the present invention pertains to methods of treating or preventing progressive neurodegenerative diseases and its associated symptoms by administration of a combination of geranylgeranylacetone (teprenone) and ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), or pharmaceutically acceptable salts thereof. | 2015-12-24 |
20150366848 | METHODS OF TREATING AND PREVENTING VASCULAR INSTABILITY DISEASES - Methods are provided of treating and preventing stroke diseases, such as cerebral cavernous malformation, by the administration of tempol and/or cholecalciferol. | 2015-12-24 |
20150366849 | CRYSTALLINE N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINY- L)PHENYL]ACETAMIDE MONO MESYLATE MONOHYDRATE HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION RANGE AND A SPECIFIC SURFACE AREA RANGE FOR USE IN PHARMACEUTICAL FORMULATIONS - The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof. | 2015-12-24 |
20150366850 | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof - The present invention relates to a modified release pharmaceutical composition of dexmethylphenidate or salts thereof. In particular, the present invention relates to a modified release pharmaceutical composition comprising plurality of components exhibiting both immediate and extended release of dexmethylphenidate or salts thereof. The composition may provide therapeutically effective plasma concentration over a period of 24 hours to treat attention deficit hyperactivity disorder when administered to a patient in need thereof. The invention also includes process of preparing such composition. | 2015-12-24 |
20150366851 | OSTEOPONTIN PRODUCTION INHIBITOR CONTAINING DICTYOPYRONE DERIVATIVE OR DIHYDRODICTYOPYRONE DERIVATIVE AS ACTIVE INGREDIENT - Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. | 2015-12-24 |
20150366852 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication - O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug. | 2015-12-24 |
20150366853 | Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds - This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: | 2015-12-24 |
20150366854 | OPHTHALMIC COMPOSITION - Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. | 2015-12-24 |
20150366855 | MUSCARINIC ANTAGONISTS AND COMBINATIONS THEREOF FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses. | 2015-12-24 |
20150366856 | COMPOUNDS AND METHODS FOR MODULATING FXR - The present invention relates to compounds of Formula (I), | 2015-12-24 |
20150366857 | Antimicrobial Compositions with Effervescent Agents - The present invention relates to pharmaceutical compositions comprising a quinolone carboxylic acid derivative antimicrobial agent and an effervescent agent. These compositions have improved gastrointestinal tolerability and/or reduced potential to cause gastrointestinal side effects. These compositions are useful for oral administration, for treating, preventing, or reducing the risk of microbial infections. | 2015-12-24 |
20150366858 | Methods for Treating Infections - The present invention relates to methods for treating, preventing, or reducing the risk of microbial infections while minimizing adverse gastrointestinal effects using a two-stage dosing regimen comprising about 1 to about 7 days of intravenous administration followed by about 1 to about 14 days of oral administration of an antimicrobial agent. | 2015-12-24 |
20150366859 | SOLID DISPERSION COMPRISING AMORPHOUS CILOSTAZOL - The present invention relates to a solid dispersion comprising cilostazol, and methacrylic acid copolymer S and/or methacrylic acid copolymer L, which is characterized in that cilostazol is retained in an amorphous state in a gastrointestinal tract for a certain period after oral administration. | 2015-12-24 |
20150366860 | COMPOSITIONS AND METHODS FOR WEIGHT LOSS IN AT RISK PATIENT POPULATIONS - The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes. | 2015-12-24 |
20150366861 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 2015-12-24 |
20150366863 | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof - The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a pharmaceutical composition comprising metformin and sitagliptin or salts thereof which is glidant and/or surface active agent. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes. | 2015-12-24 |
20150366864 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDA- ZIN-3-AMINE - The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form. | 2015-12-24 |
20150366865 | A METHOD OF TREATING OBESITY - A method of treating obesity and obesity-related disorders in a mammal is provided. The method comprises the step of administering to the mammal a compound that inhibits the synthesis or activity of peripheral serotonin, including a Tph1 inhibitor or a serotonin receptor inhibitor. | 2015-12-24 |
20150366866 | METHODS OF TREATING CHOLANGIOCARCINOMA - Methods and compositions for treating cholangiocarcinoma. | 2015-12-24 |
20150366867 | METHODS OF TREATING ATHEROSCLEROSIS OR MYELOPROLIFERATIVE NEOPLASMS BY ADMINISTERING A LYN KINASE ACTIVATOR - This invention provides a method of treating a subject suffering from atherosclerosis or a myeloproliferative neoplasm which comprises administering to the subject an amount of a Lyn kinase activator effective to activate Lyn kinase so as to thereby treat the subject. | 2015-12-24 |
20150366868 | CANCER TREATMENT METHOD - A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines. | 2015-12-24 |
20150366869 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES - The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. | 2015-12-24 |
20150366870 | NOVEL COMPOUNDS - The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A): | 2015-12-24 |
20150366871 | Increased Dosage of Efavirenz for the Treatment of Cancer - The invention is based on the finding that an increased daily dose of Efavirenz should be used for the treatment of cancer compared to the daily dose used in the treatment of AIDS. The invention thus relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a dose generating an Efavirenz plasma concentration in said patient superior to 3000 ng/ml. It further relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a daily dose of at least 1800 mg, in particular between 1800 and 2200 mg. It also relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, in which the daily dose of Efavirenz is optimized after administration of a preliminary daily dose and measure or Efavirenz plasma concentration. It also relates to a unique dosage form of Efavirenz, comprising Efavirenz in an amount generating an Efavirenz plasma concentration in said patient superior to 3000 ng/ml, and a pharmaceutically acceptable carrier. | 2015-12-24 |
20150366872 | CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13- ,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B][1,3]OXAZEPINE-1- 0-CARBOXAMIDE - The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I. | 2015-12-24 |
20150366873 | COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO-[4,3-A]]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OF METABOLIC DISORDERS - The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE10). In particular, the invention relates to combinations of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051324 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. | 2015-12-24 |
20150366874 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors - The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof | 2015-12-24 |
20150366875 | PRE-MIX COMPOSITION FOR CATTLE - The present invention concerns a premix composition for feeding cattle, comprising:
| 2015-12-24 |
20150366876 | Use of Inhibitors of Acid Sphingomyelinase to Treat Acquired and Inherited Retinal Degenerations - A method of treating retinal diseases is disclosed that includes the step of administering an effective amount of a composition including an ASMase inhibitor to a retinal disease patient, wherein at least one disease symptom is either lessened or progression of the symptom is delayed. | 2015-12-24 |
20150366877 | METHODS OF TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION AND DISEASES WITH BROMODOMAIN INHIBITORS - Methods of inhibiting replication of human cytomegalovirus (HCMV) are disclosed. In various configurations, these methods comprise administering a therapeutically effective amount of a bromodomain inhibitor to a subject in need thereof. Bromodomain inhibitors including methyltriazolodiazepine-related compounds, 3,5-dimethylisoxazole-related compounds, 3-methyldihydroquinazolinone-related compounds, N-acetyl-2-methyltetrahydroquinoline-related compounds, quinazolone-related compounds, diazobenzene-related compounds, and triazolopyridazine-related compounds can be used to inhibit viral replication. | 2015-12-24 |
20150366878 | PHEROMONE COMPOSITIONS AND THEIR USE TO MODIFY BEHAVIOR IN DIFFERENT VERTEBRATE SPECIES - A composition comprising Androstenone is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the Androstenone is a naturally occurring pheromone. | 2015-12-24 |
20150366879 | DIFLUPREDNATE EMULSION COMPOSITION CONTAINING ANTIMICROBIAL METAL - The present invention provides a difluprednate emulsion composition showing immediate effectiveness of preservative efficacy. The immediate effectiveness of preservative efficacy is achieved by adding an antimicrobial metal (excluding zinc). The present invention also provides a method of conferring immediate effectiveness of the preservative efficacy to an emulsion composition comprising difluprednate, the method includes preparing an emulsion composition comprising difluprednate and an antimicrobial metal (excluding zinc). | 2015-12-24 |
20150366880 | COMPOSITIONS AND METHODS FOR TREATING BONE DISEASES AND BROKEN BONES - Disclosed herein are methods of promoting osteogenesis in a subject, comprising administering a composition comprising a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting osteogenesis in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of bone disease or the treatment of broken bones. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 2015-12-24 |
20150366881 | System and Method for Diagnosis and Treatment - This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment. | 2015-12-24 |
20150366882 | System and Method for Diagnosis and Treatment - This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease. | 2015-12-24 |
20150366883 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR - A method of treating ovarian cancer by administering a PKC inhibitor is presented herein. It was found that administering a PKC inhibitor, such as ACPD or ICA-1, to ovarian cancer cells inhibited cancer cell proliferation. | 2015-12-24 |
20150366884 | COMPOSITIONS AND METHODS FOR CANCER THERAPY - The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier. | 2015-12-24 |
20150366885 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. | 2015-12-24 |
20150366886 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT - The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer. | 2015-12-24 |
20150366887 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs. | 2015-12-24 |
20150366888 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs. | 2015-12-24 |
20150366889 | PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA - Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria. | 2015-12-24 |
20150366890 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS - The methods and compositions described herein relate to the treatment of fungal infections, e.g. by potentiating the sensitivity of fungi to anti-fungal agents. | 2015-12-24 |
20150366891 | Edible Energy Composition - An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, preservatives, and the like. | 2015-12-24 |
20150366892 | USE OF HEAT SHOCK PROTEIN INHIBITOR IN PREPARING PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS AND HEPATOMA - The present invention is directed to a use of a heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatitis by scavenging hepatitis B virus-infected cells. The heat shock protein inhibitor is selected from a group including VER-155008, Pifithrin-μ, and pharmaceutical acceptable salts thereof. The present invention is also directed to a use of a heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatoma. | 2015-12-24 |
20150366893 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS - The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2015-12-24 |
20150366894 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS - Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-OCH | 2015-12-24 |
20150366895 | CANCER THERAPY USING miRNAs - The present invention relates generally to methods and compositions for the treatment of cancers expressing the type 1 insulin-like growth factor receptor (IGF1R) or a constituent of an IGF1R signaling pathway, in particular melanoma, using the microRNA miR-7-5p. Also provided are methods for increasing the sensitivity of such cancers to therapeutic agents. | 2015-12-24 |
20150366896 | Dietary composition having mixed polysaccharides derived from Lucid Ganoderma, Lycium barbarum and Polygonatum sibiricum and method of its preparation - The present invention discloses a Lucid | 2015-12-24 |
20150366897 | STEM CELL MICROPARTICLES AND miRNA - This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601). Identified miRNAs include hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532. | 2015-12-24 |
20150366898 | METHODS FOR TREATING OVERWEIGHT OR OBESITY - The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day. | 2015-12-24 |
20150366899 | Methods and Compositions for the Disruption of Biofilms - The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms. | 2015-12-24 |
20150366900 | CONDUCTIVE BIOMATERIAL FOR ENHANCEMENT OF CONDUCTION IN VITRO AND IN VIVO - A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia. | 2015-12-24 |
20150366901 | Methods of Treating Heart Failure - The present invention relates to the discovery that the administration of nitrate is an effective therapy for improving short-term and long-term outcomes in patients with heart failure, including heart failure with preserved ejection fraction (HFpEF). Thus, the present invention provides compositions and methods for the treatment or prevention of heart failure, including HFpEF, in a subject in need thereof. | 2015-12-24 |
20150366902 | TREATMENT OF NEUROLOGICAL DISORDERS - A treatment of a neurological disorder, including hypoxia, oxygen-glucose deprivation and acute brain trauma in a subject involves administering an effective amount of selenate or a pharmaceutically acceptable salt thereof to the subject. The treatment prevents incurring a symptom, holds in check a symptom or treats an existing symptom of the neurological disorder. | 2015-12-24 |
20150366903 | ORALLY-ADMINISTRABLE COMPOSITIONS COMPRISING STABLE AMORPHOUS CALCIUM CARBONATE - The present invention provides orally-administrable compositions comprising stable amorphous calcium carbonate (ACC). The compositions are preferably prepared as solid dosage forms such as tablets, capsules and powders. The present invention further provides methods for supplementing oral calcium intake in subjects and as well as methods for treating osteoporosis, osteomalacia and related diseases. | 2015-12-24 |
20150366904 | ASSEMBLY OF MICELLE AGGREGATES OF SURFACTANT MICELLES AND SILVER NANOPARTICLES AND USE AS ANTIBACTERIAL AGENT - An assembly of micelle aggregates, wherein each aggregate comprises micelles of an anionic surfactant and nano-sized particles of metallic silver. A product comprising such assemblies for use in treating or preventing bacterial infections. | 2015-12-24 |
20150366905 | RADIATION/CHEMOTHERAPY SENSITIZER TO BE USED FOR INTRATUMORAL LOCAL INJECTION AND FOR CONTROLLED RELEASE OF HYDROGEN PEROXIDE WITH HYDROGEL AS CARRIER - The present invention provides a radiation sensitizer or anti-cancer chemotherapy sensitizer that prevents the decomposition of hydrogen peroxide for a longer period of time, and that maintains its effect. The radiation sensitizer or anti-cancer chemotherapy sensitizer according to the present invention is characterized by using hydrogen peroxide together with a hydrogel containing a crosslinked gelatin gel. | 2015-12-24 |
20150366906 | ALKALINE DRINK - Alkaline drink compositions buffered to have a neutral to alkaline pH and methods of treatment using the same. | 2015-12-24 |
20150366907 | METHODS OF TREATING IRON DEFICIENCY WITH SOLUBLE FERRIC PYROPHOSPHATE - The invention provides for methods of treating iron deficiency and methods of reducing or eliminating the dose of erythropoiesis stimulating agent for increasing or maintaining hemoglobin levels in the target range in a subject suffering from anemia comprising administering soluble ferric pyrophosphate in an amount effective to maintain or increase Hgb levels in the subject. | 2015-12-24 |
20150366908 | SILICA-COATED CALCIUM SALT COMPOSITIONS - A composition including calcium salt and silica, wherein the silica is in the form of a silicate that is adsorbed onto the surface of the calcium salt, wherein the silica is not incorporated into the structure of the calcium salt, and wherein the composition is bioactive. | 2015-12-24 |
20150366909 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS - The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders. | 2015-12-24 |
20150366910 | NATURAL KILLER CELLS FROM PLACENTA - Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood. | 2015-12-24 |
20150366911 | METHODS FOR REJUVENATING RED BLOOD CELLS - Methods for transfusing blood to a mammalian subject. The method includes obtaining a unit of blood, rejuvenating the blood with an enhancement composition, measuring 2,3-DPG concentration of the blood, and delivering the blood to a subject. | 2015-12-24 |
20150366912 | APPLICATION AND PHARMACEUTICAL COMPOSITION OF PREACTIVATED AND DISAGGREGATED SHAPE-CHANGED PLATELETS - Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10 | 2015-12-24 |
20150366913 | Biologic Scaffold For Prevention of Pulmonary Fibrosis - Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject. | 2015-12-24 |
20150366914 | Methods for Mobilizing Hematopoietic Stem Cells - Disclosed are methods of mobilizing hematopoietic cells in a subject by administering to the subject a combination of Flt3 ligand (FLT3L) and a cell adhesion inhibitor. Also disclosed are methods of mobilizing hematopoietic cells in a cell culture population by contacting the cell culture population with Flt3 ligand. Mobilized hematopoietic cells can subsequently be harvested and used for hematopoietic cell transplantation. Further disclosed are compositions comprising a FLT3L, compositions comprising FLT3L and a cell adhesion inhibitor, and composition comprising FLT3L and Plerixafor. | 2015-12-24 |
20150366915 | PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF - This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients. | 2015-12-24 |
20150366916 | METHOD FOR PRODUCING A PLURALITY OF TEETH FROM ONE ISOLATED TOOTH GERM - The object of the present invention is to provide a method for manufacturing multiple teeth from one isolated tooth germ in order to increase the absolute number of tooth germs that can be employed for transplantation. | 2015-12-24 |
20150366917 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE - A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease. | 2015-12-24 |
20150366918 | METHOD OF CONSTRUCTING MASSES OF MYOCARDIAL CELLS AND USE OF THE MYOCARDIAL CELL MASS - The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. | 2015-12-24 |
20150366919 | SYNBIOTICS COMBINATION FOR BRAIN IMPROVEMENT - The invention relates to nutritional compositions with | 2015-12-24 |
20150366920 | METHOD FOR PREVENTING AND/OR TREATING INFECTIONS, COLONISATIONS, OR ILLNESSES RELATED TO STAPHYLOCOCCUS AUREUS, PSEUDOMONAS AERUGINOSA, STREPTOCOCCUS PYOGENES, ENTEROCOCCUS FAECIUM, ENTEROBACTER CLOACAE, PROTEUS MIRABILIS, BACTEROIDES FRAGILIS, STAPHYLOCOCCUS EPIDERMIDIS, PROPIONIBACTERIUM ACNES, CANDIDA ALBICANS AND/OR MALASSEZIA FURFUR - The subject matter of the present invention is a bacterium or a mixture of bacteria having an antagonistic activity with respect to strains of | 2015-12-24 |
20150366921 | HERBAL EXTRACT AND A METHOD OF TREATING LIVER CANCER - The invention discloses an herbal extract of treating liver cancer, wherein a method of producing the herbal extract comprising the steps of: blending | 2015-12-24 |
20150366922 | Method of Processing Rhinacanthus nastutus (L.) Kurz - The invention discloses a method of processing | 2015-12-24 |
20150366923 | ALLAMANDA CATHARTICA EXTRACTS AND METHODS OF USE - Methods of using extracts of | 2015-12-24 |
20150366924 | GINSENOSIDE COMPOSITION - The object of the present invention is to provide a ginsenoside composition which can obtain specific and excellent result in terms of efficacy, to various symptoms and diseases. | 2015-12-24 |
20150366925 | Therapeutic Compounds - The invention features therapeutic compounds useful for the treatment of skin diseases (e.g., psoriasis and eczema), infections (microbial, viral, and fungal), and wounds (e.g., cuts and burns). The compounds of the invention include therapeutically-effective amounts of L-Arginine, undecylenic acid, and | 2015-12-24 |
20150366926 | SUPPLEMENT COMPOSITION - A supplement composition comprising materials derived from | 2015-12-24 |
20150366927 | WATER DISPERSIBLE COMPOSITION AND METHOD FOR PREPARING SAME - The invention pertains to a water dispersible, preferably a powder composition of water extractible bioactive components of exclusively fruit or vegetable or plant origin. These components are obtainable by: a) subjecting a selected fruit or vegetable or plant material to homogenisation in weak alkaline conditions and at moderate temperature; b) separating the liquid extract from the homogenised mass and subsequently bringing it to neutrality; and c) eventually concentrating or drying, preferably by freeze drying, the neutralized liquid extract. The composition can be used as primary composition in the preparation of a food product for oral administration, a food supplement, a pet food product, a pet food supplement, a cosmetic preparation or a pharmaceutical preparation. | 2015-12-24 |